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Since the earliest attempts at human liver trans-
plantation, 1 research in experimental animals has 
had an important and intimate relationship with 
clinical practice.2-4 Evidence obtained in animals 
has been transferred to the clinics and problems 
encountered in the patients have been taken back to 
animals for clarification.5 In this review we describe 
examples of this flux, as well as the development of 
operative techniques and the significance of team 
construction in the laboratory as a preparatory step 
for clinical practice. 
KINDS OF LIVER TRANSPLANTATION 
There are two general approaches to transplan-
tation of the liver. With one method, an extra 
(auxiliary) liver is inserted at an ectopic site, 
without removal of the host liver. The other is to 
transplant the homograft orthotopically after total 
removal of the native liver. 
Auxiliary Liver Transplantation 
The first experiments with liver transplantation 
were performed by Welch,2 who placed the extra 
canine livers in the right paravertebral gutter or pel-
vis (Fig. 1). The hepatic arterial supply was derived 
from the aorta or iliac artery. The portal inflow was 
via the distal iliac vein or inferior vena cava and the 
outflow was into the proximal iliac vein or vena 
cava. The gallbladder was anastomosed to the duo-
From the Department oj Surgery, Unviersity oj Pittsburgh 
Health Center, University oj Pittsburgh, Pennsylvania. 
Reprint requests: Dr. Starzl, Dept. of Surgery, 3601 Fifth 
Ave., Room 103, Falk Clinic, Pittsburgh PA 15213. 
denum for biliary drainage. The livers produced bile 
for several days and then ceased to function. 
Auxiliary liver transplantation was envisioned 
by Welch as a therapeutic possibility for patients 
with liver cirrhosis or non-neoplastic hepatic dis-
eases. Many clinical trials with this procedure have 
been recorded. All such attempts failed except for 
two successful cases reported from New York6 and 
Paris.7 The results obtained in animals were inferior 
to those with orthotopic allografts, partly because 
the extra graft atrophied rapidly.8,9 One hypothesis 
was that the atrophy of the liver was the result of 
an inadequate portal flow, 10, II but experiments 
from our laboratory first suggested8,9 and then 
proved 12 that the liver atrophied from interliver 
competition in which the extra liver failed to receive 
some metabolite or other substance in the portal 
blood. 
Such atrophy could be prevented by diverting 
the nonhepatic splanchnic venous blood away from 
the host liver and through the graft.9,12 Later, 
endogenous insulin as well as other undefined 
multiple hepatotrophic factors found in splanchnic 
venous blood were found to play a central role in 
the maintenance of liver cell integrity.I3-16 Thus, 
auxiliary liver transplantation has lost much favor 
in actual practice. Nevertheless, auxiliary transplan-
tation has been a valuable tool for the investigation 
of hepatotrophic physiology.17 
Orthotopic Liver Transplantation 
The first experimental orthotopic transplanta-
tion was mentioned by Cannon18 in 1956, but with 
so little information that his publication is rarely 
cited. Two separate research programs were estab-
lished in 1958, one in Boston3 and the other in 
Chicago,4 with a maximum survival in untreated 
Publisher: Thieme Inc., 381 Park Avenue South, New York, NY 10016 309 
310 
FIG. 1. Auxiliary liver transplantation in dogs by a modifi-
cation of Welch's original technique. Note that the reconsti-
tuted portal blood supply is from the distal inferior vena cava. 
Cholecystoduodenostomy is performed. (Reproduced with per-
mission from Starzl et al.B) 
dogs of 12 and 20.5 days, respectively. The opera-
tive technique that is now employed for dogs in our 
laboratory is essentially the same as described 
before,4 but several significant modifications have 
been made. 19 The techniques of clinical liver trans-
plantation also are modifications of this original 
laboratory procedure.ZO,Zl 
ANESTHESIA FOR ORTHOTOPIC 
TRANSPLANTATION IN DOGS 
Animals are fasted from the evening before the 
operation and the weights of the donor and recipient 
are closely matched. Pairs weighing as little as 7 kg 
and as much as 40 kg have been used. Under intra-
venous induction with 25 to 30 mg/kg thiopental 
sodium, a cuffed endotracheal tube is inserted into 
the trachea and the dogs are placed on respirators. 
In recipient animals ventilation is with an air-
oxygen mixture (FIOz of 0.3), and 5 cm HzO of 
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positive expiratory pressure is applied to keep the 
arterial carbon dioxide tension at 30 to 35 mmHg. 
Maintenance of anesthesia is by the intravenous 
injection of 2 mg/kg ketamine every 20 to 30 
minutes, and 0.5 mg pancuronium. No ketamine 
is given after revascularization of the graft. The 
arterial pressure and central venous pressure are 
monitored. Approximately, 2 to 3 liters of electro-
lyte or plasma solution plus 2 units of blood usually 
are given intraoperatively. Low-dose dopamine is 
given during and after the bypass period. Calcium 
chloride and sodium bicarbonate are given when 
necessary to correct abnormalities of ionized cal-
cium and acid-base balance, especially just after the 
revascularization and unclamping of the abdominal 
aorta. Frequent measurements of blood gases and 
electrolytes are useful. External heating with 
blankets or lamps is applied because the body 
temperature usually decreases to 32 to 33°C by the 
end of the operation. In canine liver transplanta-
tion, perfect anesthesia is one of the most important 
factors if the operation is to succeed. 
SURGICAL TECHNIQUE 
Donor Operation 
Our original technique is still used.4 The 
abdominal cavity is entered through a midline in-
cision. The dissection starts from the abdominal 
aorta above the iliac bifurcation and advances up-
ward by ligating and dividing the right and left 
renal arteries, small tributaries, and lumbar arteries. 
When the crura of the diaphragm are reached and 
divided, the celiac axis and superior mesenteric 
artery are easily isolated. After dividing the left 
gastric and splenic arteries, the common hepatic 
artery is skeletonized distally into the lesser sac. 
Then, the duodenum and stomach are retracted 
downward to expose the hepatic hilum. The fundus 
of the gallbladder is incized and irrigated with nor-
mal saline to avoid autolysis by bile during the 
ischemic period. The common bile duct is ligated 
and divided below the entrance of the cystic and 
lowest hepatic ducts. The gastroduodenal artery is 
divided near the duodenum. The portal vein is 
cleaned off down to the confluence of the superior 
mesenteric vein and the splenic vein. A cannula is 
inserted into the latter for perfusion of cold fluids. 
The gastrohepatic, falciform, and left and right 
triangular and coronary ligaments are divided. The 
connective tissue attaching the retrohepatic vena 
cava is bluntly dissected by lifting the caudate lobe 
gently. The liver is then retracted to the left and 
-------------------------------- -------------------
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after dividing the right triangular ligament, the 
suprahepatic vena cava is dissected free circum-
ferentially. When the infrahepatic vena cava above 
the entrance of the adrenal veins is encircled, the 
donor liver becomes completely isolated. 
The distal aorta is then cannulated to collect 2 
units of blood for transfusion. After ligating the 
superior mesenteric artery and vein, perfusion and 
cooling of the liver is commenced through the can-
nula in the splenic vein with 2 liters of cold lactated 
Ringer's solution at the same time as the dog is ex-
sanguinated into the blood collection bags. The 
liver is then removed by transecting the portal vein, 
the upper abdominal aorta, and the vena cava 
above and below the liver, leaving enough vessel 
lengths for anastomoses (Fig. 2). 
Veno-Venous Bypasses in the Dog 
When the technique of liver transplantation 
was developed in dogs,3,4 operative survival re-
quired veno-venous bypasses that transmitted blood 
from the inferior vena cava and the portal vein to 
the upper part of the body while the venous systems 
were obstructed during the anhepatic phase of the 
Cholecysto -
duodenostomy 
\ 
\ 
\ 
FIG. 2. Orthotopic liver transplantation in dogs. (Repro-
duced with permission from Kam et a1.19 ) 
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procedure. Without bypasses, the capillary beds 
were ruined in dogs by acute venous hypertension, 
even with occlusion times as short as 30 minutes; 
the animals died of immediate or delayed irreversi-
ble shock. The original bypasses were used without 
heparinization or pumps (Fig. 3). A single bypass 
was used with our original technique,4 since a 
temporary portacaval shunt was constructed to con-
nect the splanchnic and vena caval systems (Fig. 3). 
In 1982 and 1983, a pump-driven veno-venous 
bypass system without recipient heparinization was 
developed, tested in dogs,22 and eventually brought 
to the clinical operating room.23 ,24 Then, it became 
possible to modify and improve several aspects of 
the human recipient operation, including the tech-
nique of hepatectomy.25 The bypass system has 
revolutionized clinical liver transplantation, and it 
has opened up new horizons of potential research in 
dogs and other animals. Thus, a description of the 
techriique as used in dogs is in order. 
FIG. 3. Method used in dogs for decompression of the 
inferior vena caval and splanchnic systems during removal 
of recipient liver and replacement with a homograft. Note 
that a preliminary portacaval shunt has been placed. By means 
of this temporary anastomosis, the two venous systems are con-
nected, allowing their decompression with a single external by-
pass. (Reproduced with permission from Starzl et a1.4 ) 
312 
The technique is that of Denmark et al,22 as 
modified by Kam et al. 19 The inferior vena caval 
system is drained via the proximal femoral vein 
after ligation of the distal femoral vein. Splenec-
tomy is performed and the central splenic vein is 
cannulated to drain the splanchnic bed (Fig. 4). 
Venous reentry is via the external jugular vein (Fig. 
4). All of the cannulas are standard no. 12-16 chest 
tubes (Argyle Division of Sherwood Medical, St. 
Louis, MO). 
The extracorporeal bypass includes a 3/8 inch 
(internal diameter) Tygon (Norton Industrial 
Plastics, Akron, OH) tubing interrupted with a cen-
trifugal pump (Bio-Medicus, Minnetonka, MN), 
and primed with 250 ml Plasmalyte (Fig. 4). An 
electromagnetic probe on the venous return side is 
used to measure flow. 
The venous bypass time is that required to 
complete the recipient hepectectomy, obtain hemo-
stasis in the hepatic fossa, and perform the venous 
anastomoses. Usually, the suprahepatic caval, infra-
hepatic caval, and portal anastomoses are carried 
Ext. juq._ 
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FIG. 4. Pump-driven veno-venous bypass used in dogs for 
decompression of inferior vena caval and splanchnic 
systems during anhepatic phase. (Reproduced with 
permission from Kam et a1.19 ) 
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out while on bypass before revascularizing the 
portal vein (Fig. 2). In a few animals, the portal 
vein is revascularized after only the suprahepatic 
caval and portal anastomoses. This modification 
reduces the cold ischemia time, but it necessitates a 
period of low veno-venous bypass flow, since only 
the vena caval bed is being drained while the third 
anastomosis is performed. The aortic anastomosis is 
carried out after the bypass is terminated, after all 
cannulas had been removed, and not until good 
hemostasis has been obtained (Fig. 2). 
In 40 dogs, the flow range during the bypass 
was 200 to 1500 mllminute and the bypass time was 
53.1 ± 12.9 (SD) minutes, ranging from 34 to 82 
minutes. Two dogs died suddenly of pulmonary 
emboli and two others had fibrin formation in the 
system that caused no complications. Otherwise the 
bypass technique was trouble-free. 
Recipient Operation 
The recipient operation is performed through a 
midline incision. Before starting dissection of the 
liver, the abdominal aorta below the left renal vein 
is cleaned for the anastomosis. Attention is taken 
not to injure the cisterna chyli that runs behind the 
abdominal aorta. The dissection of the host liver is 
similar to the donor operation, the difference being 
that ligation and division of the hepatic arteries and 
biliary ducts is at a high level in the liver hilum. 
Having completed the dissection of the recipient 
liver, the animal is placed on the veno-venous 
bypass, as just described. The portal vein, the infra-
hepatic vena cava above the right adrenal vein, and 
the suprahepatic vena cava are cross-clamped. 
When the suprahepatic vena cava, the portal vein, 
and the infrahepatic vena cava are cut, the host 
liver can be removed. 
The vascular anastomoses of the graft start 
with the suprahepatic vena cava, using an everted 
running suture with 5-0 polypropylene. The infra-
hepatic vena cava and portal vein anastomoses are 
done with running 6-0 polypropylene, usually in this 
order as described in the preceding section. After 
the veno-venous bypass is discontinued and bleeding 
from the anastomoses is completely controlled, 
hepatic arterial flow is reconstructed with an end-
to-side aorta-to-aorta anastomosis with running 6-0 
polypropylene suture (Fig. 2). The air. inside of the 
aorta is flushed with blood and the proximal 
opening of the donor aorta is doubly ligated. Biliary 
reconstruction is with cholecystoduodenostomy 
(Fig. 2) with an inner layer of 4-0 polyglycolic acid 
suture and an external layer of silk. After con-
trolling the bleeding, the abdominal wall is closed in 
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two layers and the skin is approximated with a 
running subcutaneous suture with 2-0 polyglycolic 
acid. 
Using a two-team approach, the donor 
operation usually takes ll1z hours and the recipient 
hepatectomy requires about 1 hour. The vascular 
anastomoses require another 1 to ll1z hours. Thus, 
the total recipient operation time is about 4 hours. 
In the first consecutive 30 transplantations using 
this method, there was a 24-hour survival of 730,10 
and a 5-day survival of 60%. 
PROBLEMS OF LIVER TRANSPLANTATION 
SUSCEPTIBLE TO ANIMAL RESEARCH 
Preservation 
The liver is extremely sensitive to ischemia and 
livers removed at normal temperature become un-
suitable for transplantation within 20 to 30 min-
utes.3,4 The first attempt to extend this permissible 
ischemia time by core cooling of the graft was 
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achieved with preliminary total body hypothermia 
of the donor (to 30°C) followed by perfusion of the 
excised liver with a chilled lactated Ringer's 
solution.4 Those organs could support the life of 
recipients dogs if revascularized as orthotopic 
homografts within 2 hours. Because of the extreme 
time limitation, further efforts to cool the entire or 
the lower half of the body with an extracorporeal 
heart-lung apparatus were attempted for 2 to 8 
hours in dogs.26 All animals died within 5 days 
after transplantation. Subsequently, a combination 
of hyperbaric oxygenation and hypothermic perfu-
sion was used.27,28 The livers thereby preserved 
(Fig. 5) for 8 to 12 hours always provided life-sus-
taining function after transplantation. Three of five 
recipients of livers preserved for 24 hours survived 
more than 8 days until they died of rejection. 
Although successful, the technique was too complex 
to be widely applicable. 
In 1976, core cooling with Collins' solution, 
which has a composition similar to intracellular 
fluid, was proved to allow safe preservation of the 
liver for up to 18 hours in dogs and 10 hours in 
Vacuum 
FIG. 5. Preservation unit. The perfusion pumps are located outside the hyperbaric chamber; 
the organ receptacle, the oxygenator, and the venous reservoir are inside. The various chamber 
inlets permit sam piing of the perfusate, gas sterilization, and oxygen delivery and removal. The 
temperature is electronically controlled. (Reproduced with permission from Brettschneider 
et al,27) 
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humans.29 This method is now applied in all of the 
clinical cases and allows multiple organ procure-
ment30 and the shipment of organs from city to city 
and between countries. Wall et a1 3! have been able 
to do the same thing with plasmalike fluids. Never-
theless, at the present time, safer and longer preser-
vation methods that are based on the response of 
liver cells to cold storage and reperfusion are under 
investigation. Such efforts may bring further insight 
into mechanisms involved in liver preservation and 
pathophysiologic changes of the liver after trans-
plantation. 
Immunosuppression 
Without immunosuppression, dogs receiving 
liver allografts inevitably die of rejection. In a 
recent study the mean survival time of such animals 
after both beagle-to-beagle and mongrel-to-beagle 
liver allografting was 11.8 ± 9.6 days.32 The 
longest survival was 35 days after a beagle-to-beagle 
transplantation. Survivals were somewhat longer 
than after grafting between outbred mongrel 
dogs.33-36 
Figure 6 shows the changes of hepatic function 
of untreated animals in the beagle series,3! whose 
early postoperative course was smooth. Within 4 or 
5 days, the dogs stopped eating and there was eleva-
tion of SGOT and bilirubin. Histopathology of 
rejecting livers has been well characterized)3 There 
is dense mononuclear cell infiltration, particularly 
around the smaller bile ducts and portal vein 
branches, with blast cells and mitoses. In the case 
of pigs, such evidence of rejection may not be 
10.000 
8000 
6000 
4000 
-.J 2000 
----:::l 
I-- 1000 
0 
CJ 800 
(f) 
600 
400 
200 
" I I 
2 4 6 8 10 20 30 
D 
----01 
E 
co 
~ 
-------------.... ------
SEMINARS IN LIVER DISEASE- VOL. 5, NO.4, 1985 
prominent.33 Even without immunosuppression, 
two of nine animals in older experiments in our 
laboratory survived for more than 15 months.34 
The history of clinical liver transplantation has 
been that of multiple agent immunosuppressive regi-
mens. These have been azathioprine and prednisone 
from 1963 to 1965, azathioprine, prednisone, and 
antilymphocyte globulin (ALG) between 1966 and 
1979, thoracic duct drainage, azathioprine, and 
prednisone in 1978 and 1979, and finally cyclo-
sporine (CS) and prednisone (with or without aza-
thioprine and monoclonal ALG) after 1980.24,25 In 
animals, the most precise information about immu-
nosuppression has been obtained from controlled 
experimentation in which the individual drugs were 
used alone.35,36 
The advent of Cs was revolutionary in trans-
plantation surgery.37,38 This drug, in combination 
with steroid,39 provides the highest survival rate of 
allografts that has ever been achieved, but the exis-
tence of nephrotoxicity and hepatotoxic side effects 
have been disadvantages.38 ,40,41 In 1984, a new Cs 
analogue, Nva 2-Cs was shown to provide potent 
immunosuppression with little nephrotoxicity in 
rats.42 We have compared the features of the 
original Cs and the new analogue using 46 canine 
orthotopic liver transplantations.32 The mean sur-
vival time, with an arbitrary observation limit of 90 
days, was 60.8 ± 34.4 with Nva2-Cs and 65.1 ± 
33.9 days with Cs (Fig. 7). Thus, the immunosup-
pressive properties of both drugs are almost identi-
caL Using the same oral dose, the absorption of 
Nva2-Cs was faster and more complete than Cs 
(Fig. 8). Functional abnormalities of liver and kid-
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FIG. 6. Changes in SGOT and total bilirubin of untreated dogs after orthotopic liver 
transplantation (OLTX). (Reproduced with permission from Todo et a1.32) 
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FIG. 7. Changes in the survival rate of dogs among un-
Nva2·Cs- and Cs-treated groups after orthotopic liver 
transplantation (Ol TX). (Reproduced with permission from 
Todo et al.32 ) 
ney were not noted in either group, but histopatho-
logic studies showed similar changes in the straight 
part of the proximal renal tubules. Thus, the possi-
bility of less nephrotoxicity of Nva2-Cs has not 
been proved. 
Team Construction 
The application of developments in liver trans-
plantation demands cooperation among specialists 
in different fields. The physical and social condi-
tions of the recipient candidate are closely evaluated 
by surgeons, hepatologists, psychologists, social 
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workers, and nurses. Putting together donor and 
recipient patient combinations is facilitated by coor-
dinators. The surgery as carried out today requires 
separate donor and recipient teams, the activities of 
which must be closely knit. During operation, coop-
eration among surgeons, anesthesiologists, perfu-
sionists, and nurses is essential. Even after the 
operation, the patient's care in the intensive care 
unit, ward, and outpatient clinic needs more 
specialists. 
Laboratory work with liver transplantation has 
the two objectives of performing research and of 
allowing the creation of harmonious teams which 
include surgeons, anesthesiologists, perfusionists, 
and scrub nurses. Both the donor team and the 
recipient team should have four surgeons, the team 
leader and three assistants. The roles of the sur-
geons and the steps in performing the operation are 
the same as for clinical transplantation. With exper-
ience in the laboratory, the team is more apt to 
perform perfectly in the human operating room. 
We wrote earlier "It is unlikely that anyone would 
wish to attempt clinical liver transplantation with-
out first personally recapitulating in the laboratory 
at least some of the earlier experiments in dogs or 
alternatively in pigs. "43 
CONCLUSION 
The operative techniques and several problems 
of liver transplantation in the dog are described. 
Cyclosporine 
o 10 20 30 40 50 60 70 80 90 0 10 20 30 40 50 60 70 80 90 
Days after OL TX 
FIG. 8. Changes in the blood level of Nva2·Cs and Cs in dogs after orthotopic liver 
transplantation (OlTX). (Reproduced with permission from Todo et al.32 ) 
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The continuing laboratory activity is important not 
only for research, but also for the training of teams 
planning clinical programs. 
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